Evidence map›Paper›PMID 37182159›Full record

ArticleFrontiers in oncology2023

Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.

Yu Yang, Qing Li, Jingjing Ma, Hui Kang, Zhiguang Lin, Yang Wang, Yan Ma, Bobin Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yu YangDepartment of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Qing LiDepartment of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Jingjing MaDepartment of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Hui KangDepartment of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Zhiguang LinDepartment of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Yang WangDepartment of Radiology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Yan MaDepartment of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Bobin ChenDepartment of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Fudan University · CNHuashan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary central nervous system lymphoma (PCNSL) is an uncommon variant of non-Hodgkin lymphoma (NHL) with high aggressiveness and poor prognosis. Although complete remission (CR) could be achieved with therapy, some patients remain refractory or recurrently with a worse response to salvage treatment and poor prognosis. No consensus on rescue therapy has been established currently. This study is aimed to evaluate the efficacy of radiotherapy or chemotherapy in first-time relapsed or refractory progressed PCNSL (R/R PCNSL) and analysis the prognostic factors, to explore differences between relapsed and refractory PCNSL. Methods: Totally 105 R/R PCNSL patients from Huashan Hospital between 1 January 2016 and 31 December 2020 were enrolled, underwent salvage radiotherapy or chemotherapy and received response assessments after each course. PFS1 was defined as the time from diagnosis to the first time of recurrence or refractory progression. Statistical analysis was performed with SPSS version 26.0. Results: Response and survival were analyzed over a 17.5months (median) follow-up. Compared to relapsed PCNSL ( Conclusions: Our results indicate that relapsed PCNSL responds well to inducing and salvage therapy and has a better prognosis compared to refractory PCNSL. Radiotherapy is effective for PCNSL after the first relapse or progression. Age, CSF protein level, and ocular involvement could be potential factors to predict prognosis.

Indexed as

chemotherapyprognosisradiotherapyrelapsed or refractory primary central nervous system lymphomasalvage therapy

Identifiers

PMID37182159
PMCPMC10174451
OpenAlexW4367325744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.